Uterine Fibroma.
Conditions
Interventions
Intervention 1: 500 mg Matricaria chamomile capsule standardized by Barij Essence Company and packaged by Shiraz University of Medical Sciences Pharmacology Unit and medication duration three times da
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Women with Fibroid Disease Confirmed by a Gynecologist Women who are willing to Cooperate and Submit Their Written Consent Not taking any Hormonal Medication The patient is not involved in any other diseases, including thyroid disease, endometriosis, adenomyosis and malignancies, etc. (Based on patient records) Don't be pregnant Don't be lactating Not Allergic to Chamomile and Sumac and Mefenamic Acid No History of Gastrointestinal, liver, Brain and Kidney Disease and Coagulation disorders Body Mass Index 19-29 Age range 20-49 years No history of prolonged constipation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Moderate to severe pain. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Pain measurement by using visual analogue scale.;Bleeding includes menorrhagia and menometrorrhagia. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Using a pictorial blood assessment chart, patient with the bleeding score higher than 100 will study The pre-study and post-study scores will be compared.;Frequent urination more than 7 times a day. Timepoint: Before intervention and 2 months after intervention. Method of measurement: urination will be entered into the study more than 7 times a day and the number of urination before and after the intervention will be questioned and recorded and compared by the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarziyeh Akbarzadeh
Shiraz University of Medical Sciences
Outcome results
None listed